InvivoGen's product citations
InvivoGen’s products are frequently cited in peer-reviewed publications for a wide variety of applications and uses. Browse our product citations below.
Please note: By clicking on the product name, you can access via the ‘Citations’ tab all references of the product (click ‘load more’).
Citations search
You can search by ‘Product Name’ or ‘Year’.
| Product | Citation | Year | Journal | Authors | Page |
|---|---|---|---|---|---|
| TLR4 KO Dual Reporter THP-1 Cells | Pathogen and human NDPK-proteins promote AML cell survival via monocyte NLRP3... | 2023 | PLoS One | Trova S. et al. | DOI: 10.1371/journal.pone.0288162 |
| Caspase-1 inhibitor - Ac-YVAD-cmk | Pathogen and human NDPK-proteins promote AML cell survival via monocyte NLRP3... | 2023 | PLoS One | Trova S. et al. | DOI: 10.1371/journal.pone.0288162 |
| Primocin® | Effect of aging on the formation and growth of colonic epithelial organoids b... | 2023 | Inflamm Regen. | Jo M.K. et al. | DOI: 10.1186/s41232-023-00282-6 |
| Imiquimod VacciGrade™ (R837) | Secretory leukocyte protease inhibitor modulates FcεRI-dependent but not Mrgp... | 2023 | Int Immunopharmacol | Kwiecinska P. et al. | DOI: 10.1016/j.intimp.2023.110631 |
| Puromycin | High-throughput functional screen identifies YWHAZ as a key regulator of panc... | 2023 | Cell Death Dis. | Cao F. et al. | DOI: 10.1038/s41419-023-05951-5 |
| 2'3'-cGAMP | Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of la... | 2023 | Sci Adv. | Cheng F. et al. | DOI: 10.1126/sciadv.ade6257 |
| QUANTI-Luc™: Luciferase Detection Reagent | Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of la... | 2023 | Sci Adv. | Cheng F. et al. | DOI: 10.1126/sciadv.ade6257 |
| RAW-Lucia™ ISG Cells | Single-dose injectable nanovaccine-in-hydrogel for robust immunotherapy of la... | 2023 | Sci Adv. | Cheng F. et al. | DOI: 10.1126/sciadv.ade6257 |
| G418 (Geneticin) | In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. | 2023 | Nat Commun. | Kiso M. et al. | DOI: 10.1038/s41467-023-40018-1 |
| Plasmocin® - Mycoplasma Elimination Reagent | In vitro and in vivo characterization of SARS-CoV-2 resistance to ensitrelvir. | 2023 | Nat Commun. | Kiso M. et al. | DOI: 10.1038/s41467-023-40018-1 |
| THP1-Dual™ Cells | Investigation of the enhanced antitumour potency of STING agonist after conju... | 2023 | Nat Nanotechnol. | Dosta P. et al. | DOI: 10.1038/s41565-023-01447-7 |
| QUANTI-Luc™: Luciferase Detection Reagent | Investigation of the enhanced antitumour potency of STING agonist after conju... | 2023 | Nat Nanotechnol. | Dosta P. et al. | DOI: 10.1038/s41565-023-01447-7 |
| QUANTI-Blue™ | Investigation of the enhanced antitumour potency of STING agonist after conju... | 2023 | Nat Nanotechnol. | Dosta P. et al. | DOI: 10.1038/s41565-023-01447-7 |
| RAW-Lucia™ ISG Cells | Investigation of the enhanced antitumour potency of STING agonist after conju... | 2023 | Nat Nanotechnol. | Dosta P. et al. | DOI: 10.1038/s41565-023-01447-7 |
| RAW-Lucia™ ISG-KO-STING Cells | Investigation of the enhanced antitumour potency of STING agonist after conju... | 2023 | Nat Nanotechnol. | Dosta P. et al. | DOI: 10.1038/s41565-023-01447-7 |
| Poly(I:C) HMW | RelB-deficient autoinflammatory pathology presents as interferonopathy, but i... | 2023 | J Allergy Clin Immunol. | Navarro H.I. et al. | DOI: 10.1016/j.jaci.2023.06.024 |
| ODN 1668 - TLR9 ligand | RelB-deficient autoinflammatory pathology presents as interferonopathy, but i... | 2023 | J Allergy Clin Immunol. | Navarro H.I. et al. | DOI: 10.1016/j.jaci.2023.06.024 |
| R848 (Resiquimod) | A protocol for high-throughput screening for immunomodulatory compounds using... | 2023 | STAR Protoc. | Chew K. et al. | DOI: 10.1016/j.xpro.2023.102405 |
| ODN 2395 - TLR9 ligand | A protocol for high-throughput screening for immunomodulatory compounds using... | 2023 | STAR Protoc. | Chew K. et al. | DOI: 10.1016/j.xpro.2023.102405 |
| TLR4-based adjuvant - MPLA-SM VacciGrade™ | CHO-produced RBD-Fc subunit vaccines with alternative adjuvants generate immu... | 2023 | PLoS One | Laotee S. et al. | DOI: 10.1371/journal.pone.0288486 |